Your browser is no longer supported. Please, upgrade your browser.
MRK Merck & Co., Inc. monthly Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E19.88 EPS (ttm)3.98 Insider Own0.10% Shs Outstand2.53B Perf Week2.80%
Market Cap199.98B Forward P/E13.11 EPS next Y6.03 Insider Trans-4.24% Shs Float2.52B Perf Month-2.64%
Income10.20B PEG3.31 EPS next Q1.08 Inst Own77.40% Short Float0.75% Perf Quarter1.23%
Sales48.08B P/S4.16 EPS this Y58.90% Inst Trans-1.17% Short Ratio1.41 Perf Half Y-7.77%
Book/sh10.35 P/B7.64 EPS next Y13.28% ROA12.10% Target Price93.94 Perf Year-0.40%
Cash/sh2.94 P/C26.91 EPS next 5Y6.00% ROE38.10% 52W Range65.25 - 92.64 Perf YTD-13.10%
Dividend2.44 P/FCF63.91 EPS past 5Y-1.10% ROI19.20% 52W High-14.54% Beta0.51
Dividend %3.09% Quick Ratio0.90 Sales past 5Y2.10% Gross Margin72.20% 52W Low21.33% ATR2.07
Employees71000 Current Ratio1.10 Sales Q/Q11.50% Oper. Margin25.50% RSI (14)54.18 Volatility1.68% 2.29%
OptionableYes Debt/Eq1.07 EPS Q/Q10.30% Profit Margin21.10% Rel Volume0.47 Prev Close79.04
ShortableYes LT Debt/Eq0.83 EarningsApr 28 BMO Payout58.30% Avg Volume13.41M Price79.17
Recom1.90 SMA201.84% SMA501.94% SMA200-4.96% Volume4,190,770 Change0.16%
Feb-27-20Initiated Barclays Overweight $93
Jan-07-20Initiated RBC Capital Mkts Sector Perform $99
Oct-17-19Resumed BofA/Merrill Neutral $90
Aug-16-19Initiated SVB Leerink Outperform
Jul-03-19Initiated Mizuho Buy $97
May-28-19Initiated Goldman Neutral
May-13-19Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
May-29-20 01:36PM  Merck's Keytruda Better Than Chemotherapy for Certain Colon Cancers Motley Fool
11:35AM  Heres why Citi says stocks have rallied and why new fuel for gains is now needed MarketWatch
10:57AM  Buy Merck Stock On Vaccine Hopes Zacks
08:28AM  European agency panel recommends approval of J&J's Ebola vaccine Reuters
07:22AM  The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant Benzinga
06:00AM  Nows the Time to Buy These 3 Stocks Motley Fool
May-28-20 06:37PM  KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma Business Wire
05:00PM  Mercks KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer Business Wire
02:56PM  Merck, Pfizer share gains contribute to Dow's 86-point climb MarketWatch
01:56PM  Dow up 200 points on gains in shares of Boeing, Pfizer MarketWatch
11:34AM  ER doctor: 12-18 month coronavirus vaccine timeline 'is extremely optimistic' Yahoo Finance
11:30AM  Dow climbs 138 points on gains for shares of Boeing, Merck MarketWatch
10:56AM  Pfizer ties up with glass maker Corning for vial supply Reuters
09:53AM  Dow climbs 69 points on gains in shares of Boeing, Merck MarketWatch
06:26AM  No preferential access to Themis' potential COVID-19 vaccine - CEO Reuters
05:37AM  No preferential access to Themis' potential COVID-19 vaccine -CEO Reuters
May-27-20 10:49AM  Stock Market News for May 27, 2020 Zacks
03:38AM  Merck CEO Casts Doubt On Very Aggressive Covid-19 Vaccine Timeline SmarterAnalyst
May-26-20 04:58PM  Merck CEO Warns a Covid-19 Vaccine Could Take Longer Than 18 Months. Moderna Stock Tumbles. Barrons.com
04:42PM  Dow closes up 500 points, tests 25,000 level, on recovery hopes and vaccine news MarketWatch
04:35PM  Coronavirus latest: Tuesday, May 26 Yahoo Finance Video
04:34PM  At Last, Merck Is Diving Into Coronavirus Vaccine and Antiviral Development Motley Fool
04:30PM  US STOCKS-S&P 500 rises on economic recovery and vaccine hopes, pulls back from highs Reuters
04:08PM  Stock market news live updates: S&P 500 closes at highest since March 5 Yahoo Finance
04:00PM  US STOCKS-S&P 500 rises on economic recovery and vaccine hopes, pulls back from highs Reuters
02:45PM  Coronavirus update: Global case tally crosses 5.5 million as WHO warns of risk of second peak in current infection wave MarketWatch
02:30PM  US STOCKS-S&P 500 clears 3,000 barrier on economic recovery and vaccine hopes Reuters
01:53PM  Tuesday Morning Market Highlights GuruFocus.com
01:47PM  Coronavirus update: Novavax begins vaccine trials; Brazil reports second-highest number of cases in world Yahoo Finance
01:12PM  REFILE-US STOCKS-S&P 500 clears 3,000 barrier on hopes of recovery, vaccine Reuters
01:09PM  Here is How Hedge Funds Traded Merck & Co. (MRK) During The Crash Insider Monkey
12:37PM  Merck Announces Third-Quarter 2020 Dividend Business Wire
12:06PM  US STOCKS-S&P 500 tops 3,000 on hopes of economic recovery, COVID-19 vaccine Reuters
11:53AM  Novavax expects COVID-19 vaccine trial results in July Yahoo Finance
11:43AM  GE Is an Industrial Stock but a Covid-19 Vaccine Is the Remedy It Needs Barrons.com
10:48AM  Merck's Coronavirus Plan Of Attack: 2 Partnerships, M&A Deal Aimed At Treatment, Vaccine Development Benzinga
10:48AM  US STOCKS-S&P 500 tops 3,000 pts on hopes of economic recovery, COVID-19 vaccine Reuters
09:59AM  Novavax and Merck Fuel COVID-19 Vaccine Hopes Investopedia
09:54AM  Dow surges 600 points, S&P 500 punches above key technical level as stock-market investors focus on Novovax, Merck vaccine candidates MarketWatch
09:49AM  Merck Joins Race For Covid-19 Vaccine; Shares Rise 4.4% In Pre-Market Trading SmarterAnalyst
09:38AM  Merck and Novavax Are Lifting the Stock Market, but Regeneron is Sliding. Heres Why. Barrons.com
09:33AM  The Dow Is Rising Because Vaccines Are In the News Again Barrons.com
09:22AM  US STOCKS-Wall St set to surge at open on recovery, vaccine hopes Reuters
09:22AM  Merck's Languishing Charts Could Get Boost on New Covid-19 Initiatives TheStreet.com
07:58AM  US STOCKS-S&P 500 futures surge on recovery, vaccine hopes Reuters
07:44AM  Merck Jumps Into Search for Covid-19 Vaccine and Treatment TheStreet.com
07:26AM  Merck to buy Austrian vaccine maker as it jumps into COVID-19 race Reuters
06:51AM  Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801 Business Wire
06:49AM  Merck to buy Austrian vaccine maker as it jumps into COVID-19 race Reuters
06:49AM  IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2 Business Wire
06:47AM  Merck to Acquire Themis Business Wire
06:45AM  Merck to Announce Multiple Scientific Efforts to Combat COVID-19 Business Wire
06:45AM  Merck leaps into COVID-19 development fray with vaccine, drug deals Reuters
May-24-20 02:40PM  The Week Ahead In Biotech: ASCO Presentations In The Spotlight Benzinga
May-22-20 07:46AM  Telehealth is going to 'become the default' for patients: Ro CEO Yahoo Finance
May-21-20 03:48PM  Fmr. CDC Official: 'were not cutting any corners' on COVID-19 vaccine development Yahoo Finance Video
02:24PM  Clovis Oncology Needs a Savior GuruFocus.com
May-20-20 09:23AM  Here are the hot dogs that hedge funds have used to outperform this year MarketWatch
09:02AM  AstraZeneca, Merck Announce FDA Approval of Prostate Cancer Drug TheStreet.com
07:58AM  AstraZeneca and Merck's Lynparza gets FDA approval for prostate cancer MarketWatch
07:05AM  Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients GlobeNewswire
06:55AM  LYNPARZA® (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone Business Wire
06:26AM  AstraZeneca-Merck Lynparza Prostate Cancer Treatment Gets FDA Approval SmarterAnalyst
May-19-20 03:18PM  Johns Hopkins doctor on Trump's preventative hydroxychloroquine use: 'hopefully other people will not follow this example' Yahoo Finance Video
03:15PM  Dow's 100-point drop led by losses for Merck, Procter & Gamble shares MarketWatch
02:14PM  Dow down 36 points on losses for shares of Merck, Procter & Gamble MarketWatch
01:16PM  7 Stocks Elfun Trusts Continues to Buy GuruFocus.com
01:04PM  Dow falls nearly 100 points on losses for shares of Merck, Home Depot MarketWatch
11:53AM  Dow falls 25 points on losses in Exxon Mobil, Chevron stocks MarketWatch
10:33AM  CORRECTING and REPLACING Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer Business Wire
07:00AM  Infectious Disease Connect and ILÚM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship Business Wire
May-18-20 02:54PM  We anticipate a U-Shaped to Swoosh-Shaped recovery: Strategist Yahoo Finance Video
02:47PM  Moderna COVID-19 vaccine data is baby-step in right direction: Expert Yahoo Finance Video
May-15-20 03:13PM  U.S. FDA approves Bristol Myers' combo therapy for lung cancer Reuters
03:09PM  Trump unveils vaccine effort, says country will be back on its feet with or without one Yahoo Finance Video
02:54PM  Merck's (MRK) Keytruda Successful in Several Cancer Studies Zacks
May-14-20 02:47PM  American Express, UnitedHealth share gains contribute to Dow's 65-point climb MarketWatch
02:15PM  8 Dividend Stocks That Split the Difference Between Yield and Safety Barrons.com
01:46PM  Merck's Top Cancer Therapy Takes Another Big Leap Forward Motley Fool
10:46AM  Merck, Roche, Amgen Stocks React to Release of Cancer-Drug Data Barrons.com
08:44AM  Merck KGaA says profit could slip as fertility treatments shunned Reuters
06:55AM  Merck Just Made a Gamble That Smart Investors Should Bet on Too Motley Fool
06:45AM  Merck to Present at the UBS Virtual Global Healthcare Conference Business Wire
May-13-20 05:03PM  Dow Jones Falls Over 500 Points on Wednesday GuruFocus.com
05:00PM  New Combination Data for Mercks KEYTRUDA® (pembrolizumab) Demonstrated Clinical Benefit in Stage III Non-Small Cell Lung Cancer (NSCLC) and Reinforce Long-Term Survival in Metastatic NSCLC Business Wire
05:00PM  Mercks Novel HIF-2 Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma Business Wire
05:00PM  Mercks KEYTRUDA® (pembrolizumab) Superior to Brentuximab Vedotin (BV), a Standard of Care, in Patients With Classical Hodgkin Lymphoma (cHL) in Head-to-Head Phase 3 Trial Business Wire
05:00PM  Mercks KEYTRUDA® (pembrolizumab) Plus Chemotherapy Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Chemotherapy in Certain Patients with Metastatic Triple-Negative Breast Cancer Business Wire
02:00AM  Merck Animal Health to Acquire U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals Business Wire
May-11-20 05:40PM  US Indexes Post Some Gains Monday GuruFocus.com
May-10-20 08:51AM  AstraZeneca-Merck Ovarian Cancer Treatment Gets FDA Approval SmarterAnalyst
May-08-20 05:25PM  LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer Business Wire
04:59PM  Stocks jump despite a record 20.5M jobs lost in April Yahoo Finance Video
06:45AM  Merck Announces Virtual 2020 Annual Shareholders Meeting Business Wire
May-07-20 05:42PM  Analysts See Seattle Genetics Profitable in 2022 GuruFocus.com
02:45PM  Stocks surge despite another grim jobless claims report Yahoo Finance Video
09:55AM  Is Merck & Co., Inc.'s (NYSE:MRK) CEO Paid At A Competitive Rate? Simply Wall St.
06:59AM  Bristol Myers sees 2020 earnings holding despite coronavirus pandemic Reuters
06:55AM  Merck to Present at the BofA Securities 2020 Health Care Conference Business Wire
06:45AM  Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program Business Wire
Merck & Co., Inc. provides healthcare solutions worldwide. It operates through Pharmaceutical and Animal Health segments. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, esophageal, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. In addition, the company offers drugs for hepatocellular and merkel cell carcinoma; antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticides for sea lice in salmon; and antibiotics and vaccines for fish. Further, it provides companion animal products; diabetes mellitus treatment and anthelmintic products for dogs and cats; products to treat fleas, ticks, mosquitoes, and sandflies; horse fertility management products for swine; and dog, cat, and horse vaccines. Additionally, the company offers services and solutions that focus on engagement, clinical, and health analytics. Merck & Co., Inc. has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Almac Discovery Ltd.; and Skyhawk Therapeutics, Inc. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers; and physicians and physician distributors, veterinarians, and animal producers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BRUN LESLIE ADirectorMay 07Option Exercise0.005,00006,948May 07 04:48 PM
WEEKS WENDELL PDirectorMay 07Option Exercise0.005,00005,100May 07 04:50 PM
BRUN LESLIE ADirectorMay 07Sale75.465,000377,3001,948May 07 04:48 PM
WEEKS WENDELL PDirectorMay 07Sale76.025,000380,104100May 07 04:50 PM
Nally MichaelEVP, Chief Marketing OfficerMay 05Option Exercise76.862,345180,23712,054May 06 05:14 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 05Option Exercise76.863,283252,33129,401May 06 05:15 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 05Option Exercise76.861,29099,1497,304May 06 05:16 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 05Option Exercise76.863,752288,37982,611May 06 05:17 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 04Option Exercise77.671,904147,88479,797May 06 05:17 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 04Option Exercise77.6769253,7486,252May 06 05:16 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise77.671,21294,13626,715May 06 05:15 PM
Zachary JenniferEVP, General CounselMay 04Option Exercise77.675,772448,3119,489May 06 05:13 PM
Nally MichaelEVP, Chief Marketing OfficerMay 04Option Exercise77.671,298100,81610,274May 06 05:14 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 03Option Exercise77.6787567,96125,934May 05 04:48 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 03Option Exercise77.671,541119,6896,089May 05 04:42 PM
Gerberding Julie L.EVP Strat Comm, GI Pub PolicyJan 13Option Exercise0.0082,5480139,111Jan 15 05:15 PM
Gerberding Julie L.EVP Strat Comm, GI Pub PolicyJan 13Sale89.34102,0739,118,86537,038Jan 15 05:15 PM
Nally MichaelEVP, Chief Marketing OfficerOct 30Option Exercise0.002,28706,196Nov 01 05:07 PM
MIZELL STEVENEVP, Chief HR OfficerOct 30Option Exercise0.004,57404,574Nov 01 05:07 PM
Clyburn FrankEVP, Chief Commercial OfficerOct 30Option Exercise0.002,287073,032Nov 01 05:06 PM
Scholefield James HEVP,Chief Info&Digital OfficerOct 30Option Exercise0.0011,436011,436Nov 01 05:04 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Option Exercise0.006,427077,951Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Sale85.096,427546,85071,524Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Option Exercise0.0031,6990103,223Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Sale85.0131,6992,694,78971,524Aug 12 05:13 PM
Davis Robert MEVP, Global Svcs & CFOJun 25Option Exercise0.00216,7180354,378Jun 27 05:05 PM
Davis Robert MEVP, Global Svcs & CFOJun 25Sale85.43216,71818,514,032137,660Jun 27 05:05 PM